Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology

Alberti, C

doi:10.11138/gchir/2015.36.4.187

Cited by 17 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Drug induced RPF is a rarely reported complication in subjects following the usage of ergot alkaloids (eg, ergotamine, methysergide). 18 A previous report described a distinctive restrictive type pleuropulmonary pattern of fibrosis following long-term therapy with ergot derivatives (nicergoline, dihydroergocristine, dihydroergotamine), as opposed to typical interstitial pattern observed in other drugs. None of the cases were associated with either clinical or biological evidence of a systemic illness such as rheumatoid arthritis, ankylosing spondylitis, mixed connective tissue disease, lupus erythematosus, or inflammatory bowel disease, and vasculitic mechanism was not described in any of those cases.…”

Section: Discussionmentioning

confidence: 97%

Ergotamine Induced Retroperitoneal Fibrosis

Patra

Padhi

Padhan

et al. 2021

MJR

View full text Add to dashboard Cite

Retroperitoneal fibrosis (RPF) is an uncommon disease characterised by the presence of fibroinflammatory reaction which starts around the infrarenal portion of the abdominal aorta in the retroperitoneum and frequently entrap the ureter causing obstructive uropathy. Approximately, two thirds of the cases are idiopathic, where aetiopathogenesis is not known. Ergotamine-induced RPF, although rare, is considered under secondary group. The fibrogenic process here is thought to be due to serotonergic activity. We report a case of RPF in a young female with obstructive uropathy who had history of long-term ergotamine intake for migraine. Histopathological evaluation revealed different evolving stages of necrotising vasculitis. In addition, the patient has responded to withdrawal of offending drug along with immunosuppressive therapy. We believe, apart from serotonergic activity, ergotamine can lead to RPF through a vasculitic process which has not been reported earlier.

show abstract

Section: Discussionmentioning

confidence: 97%

Ergotamine Induced Retroperitoneal Fibrosis

Patra

Padhi

Padhan

et al. 2021

MJR

View full text Add to dashboard Cite

show abstract

“…MTX is now considered a “possible” inductive factor for retroperitoneal fibrosis (RPF). Reports of MTX causing RPF are extremely infrequent making the description of the pathogenesis elusive [ 22 ]. Paradoxically, there is (limited) data suggesting that methotrexate may be effective in combination with prednisone for the treatment of relapsing idiopathic retroperitoneal fibrosis [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

My Double Trouble: An Autobiographical Case Report of Psoriasis and Psoriatic Arthritis

Trohman¹

2021

Cureus

View full text Add to dashboard Cite

Psoriasis and psoriatic arthritis are overlapping, related, but distinct entities. Each occurs as a result of a complex combination of precipitants, genetic predispositions, and variable expression of a self-sustaining proinflammatory state. My case history and clinical course are outlined below. In addition, the epidemiology, pathogenesis, and the expanding armamentarium of treatment options, including their strengths and weaknesses, are discussed in detail.

show abstract

“…This increased serotonin via feedback mediates myofibroblast proliferation with overproduction of collagen, fibronectin, tenascin and glycosaminoglycans. 8 From our literature search, no published human studies were found exploring the effect of ergotamine on the dura mater. We postulate whether a similar rebound release of serotonin after ergotamine use could be the pathogenesis of pachymeningitis, similar to what is hypothesised to occur in other organs.…”

Section: Discussionmentioning

confidence: 99%

Long-term Ergotamine Derivative Therapy for Migraine Associated with Pachymeningitis and Sixth Cranial Nerve Palsy

Tynan

Ahmad

Thieben

2018

Neuro-Ophthalmology

View full text Add to dashboard Cite

Chronic use of ergotamine derivatives has been well described in the literature to cause retroperitoneal, pleural, pericardial and valvular fibrosis. While acute migraine treatment advances have resulted in a reduction of ergotamine derivatives prescribing, they are still considered appropriate for some patients. We report a case of diffuse pachymeningitis with symptomatic right sixth cranial nerve palsy who had a history of long-term Cafergot© suppository use. To the best of our knowledge, this is the first case to temporally associate ergotamine derivatives with pachymeningitis.

show abstract

Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology

Cited by 17 publications

References 45 publications

Ergotamine Induced Retroperitoneal Fibrosis

Ergotamine Induced Retroperitoneal Fibrosis

My Double Trouble: An Autobiographical Case Report of Psoriasis and Psoriatic Arthritis

Long-term Ergotamine Derivative Therapy for Migraine Associated with Pachymeningitis and Sixth Cranial Nerve Palsy

Contact Info

Product

Resources

About